Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Rating) Director Richard W. Mott sold 11,014 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $26.00, for a total transaction of $286,364.00. Following the completion of the sale, the director now directly owns 1,250,000 shares of the company’s stock, valued at $32,500,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Treace Medical Concepts Price Performance
Shares of NASDAQ TMCI opened at $25.94 on Friday. Treace Medical Concepts, Inc. has a 1 year low of $12.48 and a 1 year high of $26.50. The firm has a 50-day moving average of $23.57 and a 200 day moving average of $21.63. The company has a debt-to-equity ratio of 0.85, a current ratio of 5.66 and a quick ratio of 4.92.
Treace Medical Concepts (NASDAQ:TMCI – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.06. The business had revenue of $33.06 million during the quarter, compared to analysts’ expectations of $30.10 million. Treace Medical Concepts had a negative net margin of 35.87% and a negative return on equity of 51.67%. Research analysts anticipate that Treace Medical Concepts, Inc. will post -0.75 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several research firms have recently commented on TMCI. BTIG Research raised their target price on shares of Treace Medical Concepts to $29.00 in a research report on Tuesday, November 15th. Morgan Stanley lifted their price target on shares of Treace Medical Concepts from $23.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, October 11th.
About Treace Medical Concepts
Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.
- Get a free copy of the StockNews.com research report on Treace Medical Concepts (TMCI)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.